Chemical design of 99mTc-labeled probes for targeting osteogenic bone region

Mashiho Yanagi, Tomoya Uehara, Yukie Uchida, Sachiko Kiyota, Mai Kinoshita, Yusuke Higaki, Hiromichi Akizawa, Hirofumi Hanaoka, Yasushi Arano

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Radionuclide bone imaging using polynuclear 99mTc complexes of bisphosphonates is the most common clinical practice in nuclear medicine. However, the improvement in the contrast between normal and osteogenic bone regions has been required. Herein we reported a new 99mTc-labeled compound considering the increased vascular permeability of osteogenic region. We selected penta-d-Asp as both a targeting motif to hydroxyapatite (HA) and a molecular size modifier, and two penta-d-Asp molecules were conjugated with the two carboxylate residues of ethylene dicysteine (EC) selected as the 99mTc chelating moiety to prepare EC-[(d-Asp)5] 2. The molecular size, HA binding, and pharmacokinetics of 99mTc-EC-[(d-Asp)5]2 in normal mice and model rats bearing osteogenic tumor were compared to those of 99mTc-MDP and 99mTc-EC with one (d-Asp)5 motif, 99mTc-EC-(d- Asp)5. The molecular size of 99mTc-EC-[(d-Asp) 5]2 was higher than that of 99mTc-MDP and 99mTc-EC-(d-Asp)5 when determined by permeability of the 99mTc-compounds through a membrane filter (10 kDa). The HA binding of 99mTc-EC-[(d-Asp)5]2 was higher than and similar to that of 99mTc-EC-(d-Asp)5 and 99mTc-MDP. 99mTc-EC-[(d-Asp)5]2 exhibited significantly lower accumulation in normal bone of mice than did 99mTc-MDP. In osteogenic tumor bearing model rats, 99mTc-EC-[(d-Asp)5]2 accumulated in the osteogenic and normal bone region similar to and lower than 99mTc- MDP, respectively. Although further studies including the chain length of d-Asp are required, these findings indicated that the present chemical design of 99mTc-labeled probe would be applicable to develop 99mTc-labeled probes for selective imaging of osteogenic bone region as well as develop therapeutic agents using therapeutic radionuclides such as 90Y, 177Lu, 186Re, or 188Re and cytotoxic agents to osteogenic bone tumor region.

Original languageEnglish
Pages (from-to)1248-1255
Number of pages8
JournalBioconjugate Chemistry
Volume24
Issue number7
DOIs
Publication statusPublished - Jul 17 2013
Externally publishedYes

Fingerprint

Technetium Tc 99m Medronate
Bone
Bone and Bones
Bearings (structural)
Durapatite
Hydroxyapatite
Tumors
Rubiaceae
Radioisotopes
Rats
Nuclear medicine
Imaging techniques
Neoplasms
Pharmacokinetics
Nuclear Medicine
Cytotoxins
Diphosphonates
Capillary Permeability
Viperidae
Chelation

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Organic Chemistry
  • Pharmaceutical Science
  • Biomedical Engineering
  • Pharmacology

Cite this

Yanagi, M., Uehara, T., Uchida, Y., Kiyota, S., Kinoshita, M., Higaki, Y., ... Arano, Y. (2013). Chemical design of 99mTc-labeled probes for targeting osteogenic bone region. Bioconjugate Chemistry, 24(7), 1248-1255. https://doi.org/10.1021/bc400197f

Chemical design of 99mTc-labeled probes for targeting osteogenic bone region. / Yanagi, Mashiho; Uehara, Tomoya; Uchida, Yukie; Kiyota, Sachiko; Kinoshita, Mai; Higaki, Yusuke; Akizawa, Hiromichi; Hanaoka, Hirofumi; Arano, Yasushi.

In: Bioconjugate Chemistry, Vol. 24, No. 7, 17.07.2013, p. 1248-1255.

Research output: Contribution to journalArticle

Yanagi, M, Uehara, T, Uchida, Y, Kiyota, S, Kinoshita, M, Higaki, Y, Akizawa, H, Hanaoka, H & Arano, Y 2013, 'Chemical design of 99mTc-labeled probes for targeting osteogenic bone region', Bioconjugate Chemistry, vol. 24, no. 7, pp. 1248-1255. https://doi.org/10.1021/bc400197f
Yanagi M, Uehara T, Uchida Y, Kiyota S, Kinoshita M, Higaki Y et al. Chemical design of 99mTc-labeled probes for targeting osteogenic bone region. Bioconjugate Chemistry. 2013 Jul 17;24(7):1248-1255. https://doi.org/10.1021/bc400197f
Yanagi, Mashiho ; Uehara, Tomoya ; Uchida, Yukie ; Kiyota, Sachiko ; Kinoshita, Mai ; Higaki, Yusuke ; Akizawa, Hiromichi ; Hanaoka, Hirofumi ; Arano, Yasushi. / Chemical design of 99mTc-labeled probes for targeting osteogenic bone region. In: Bioconjugate Chemistry. 2013 ; Vol. 24, No. 7. pp. 1248-1255.
@article{f9d5ce9d39a243e3904919b1e319fbf1,
title = "Chemical design of 99mTc-labeled probes for targeting osteogenic bone region",
abstract = "Radionuclide bone imaging using polynuclear 99mTc complexes of bisphosphonates is the most common clinical practice in nuclear medicine. However, the improvement in the contrast between normal and osteogenic bone regions has been required. Herein we reported a new 99mTc-labeled compound considering the increased vascular permeability of osteogenic region. We selected penta-d-Asp as both a targeting motif to hydroxyapatite (HA) and a molecular size modifier, and two penta-d-Asp molecules were conjugated with the two carboxylate residues of ethylene dicysteine (EC) selected as the 99mTc chelating moiety to prepare EC-[(d-Asp)5] 2. The molecular size, HA binding, and pharmacokinetics of 99mTc-EC-[(d-Asp)5]2 in normal mice and model rats bearing osteogenic tumor were compared to those of 99mTc-MDP and 99mTc-EC with one (d-Asp)5 motif, 99mTc-EC-(d- Asp)5. The molecular size of 99mTc-EC-[(d-Asp) 5]2 was higher than that of 99mTc-MDP and 99mTc-EC-(d-Asp)5 when determined by permeability of the 99mTc-compounds through a membrane filter (10 kDa). The HA binding of 99mTc-EC-[(d-Asp)5]2 was higher than and similar to that of 99mTc-EC-(d-Asp)5 and 99mTc-MDP. 99mTc-EC-[(d-Asp)5]2 exhibited significantly lower accumulation in normal bone of mice than did 99mTc-MDP. In osteogenic tumor bearing model rats, 99mTc-EC-[(d-Asp)5]2 accumulated in the osteogenic and normal bone region similar to and lower than 99mTc- MDP, respectively. Although further studies including the chain length of d-Asp are required, these findings indicated that the present chemical design of 99mTc-labeled probe would be applicable to develop 99mTc-labeled probes for selective imaging of osteogenic bone region as well as develop therapeutic agents using therapeutic radionuclides such as 90Y, 177Lu, 186Re, or 188Re and cytotoxic agents to osteogenic bone tumor region.",
author = "Mashiho Yanagi and Tomoya Uehara and Yukie Uchida and Sachiko Kiyota and Mai Kinoshita and Yusuke Higaki and Hiromichi Akizawa and Hirofumi Hanaoka and Yasushi Arano",
year = "2013",
month = "7",
day = "17",
doi = "10.1021/bc400197f",
language = "English",
volume = "24",
pages = "1248--1255",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Chemical design of 99mTc-labeled probes for targeting osteogenic bone region

AU - Yanagi, Mashiho

AU - Uehara, Tomoya

AU - Uchida, Yukie

AU - Kiyota, Sachiko

AU - Kinoshita, Mai

AU - Higaki, Yusuke

AU - Akizawa, Hiromichi

AU - Hanaoka, Hirofumi

AU - Arano, Yasushi

PY - 2013/7/17

Y1 - 2013/7/17

N2 - Radionuclide bone imaging using polynuclear 99mTc complexes of bisphosphonates is the most common clinical practice in nuclear medicine. However, the improvement in the contrast between normal and osteogenic bone regions has been required. Herein we reported a new 99mTc-labeled compound considering the increased vascular permeability of osteogenic region. We selected penta-d-Asp as both a targeting motif to hydroxyapatite (HA) and a molecular size modifier, and two penta-d-Asp molecules were conjugated with the two carboxylate residues of ethylene dicysteine (EC) selected as the 99mTc chelating moiety to prepare EC-[(d-Asp)5] 2. The molecular size, HA binding, and pharmacokinetics of 99mTc-EC-[(d-Asp)5]2 in normal mice and model rats bearing osteogenic tumor were compared to those of 99mTc-MDP and 99mTc-EC with one (d-Asp)5 motif, 99mTc-EC-(d- Asp)5. The molecular size of 99mTc-EC-[(d-Asp) 5]2 was higher than that of 99mTc-MDP and 99mTc-EC-(d-Asp)5 when determined by permeability of the 99mTc-compounds through a membrane filter (10 kDa). The HA binding of 99mTc-EC-[(d-Asp)5]2 was higher than and similar to that of 99mTc-EC-(d-Asp)5 and 99mTc-MDP. 99mTc-EC-[(d-Asp)5]2 exhibited significantly lower accumulation in normal bone of mice than did 99mTc-MDP. In osteogenic tumor bearing model rats, 99mTc-EC-[(d-Asp)5]2 accumulated in the osteogenic and normal bone region similar to and lower than 99mTc- MDP, respectively. Although further studies including the chain length of d-Asp are required, these findings indicated that the present chemical design of 99mTc-labeled probe would be applicable to develop 99mTc-labeled probes for selective imaging of osteogenic bone region as well as develop therapeutic agents using therapeutic radionuclides such as 90Y, 177Lu, 186Re, or 188Re and cytotoxic agents to osteogenic bone tumor region.

AB - Radionuclide bone imaging using polynuclear 99mTc complexes of bisphosphonates is the most common clinical practice in nuclear medicine. However, the improvement in the contrast between normal and osteogenic bone regions has been required. Herein we reported a new 99mTc-labeled compound considering the increased vascular permeability of osteogenic region. We selected penta-d-Asp as both a targeting motif to hydroxyapatite (HA) and a molecular size modifier, and two penta-d-Asp molecules were conjugated with the two carboxylate residues of ethylene dicysteine (EC) selected as the 99mTc chelating moiety to prepare EC-[(d-Asp)5] 2. The molecular size, HA binding, and pharmacokinetics of 99mTc-EC-[(d-Asp)5]2 in normal mice and model rats bearing osteogenic tumor were compared to those of 99mTc-MDP and 99mTc-EC with one (d-Asp)5 motif, 99mTc-EC-(d- Asp)5. The molecular size of 99mTc-EC-[(d-Asp) 5]2 was higher than that of 99mTc-MDP and 99mTc-EC-(d-Asp)5 when determined by permeability of the 99mTc-compounds through a membrane filter (10 kDa). The HA binding of 99mTc-EC-[(d-Asp)5]2 was higher than and similar to that of 99mTc-EC-(d-Asp)5 and 99mTc-MDP. 99mTc-EC-[(d-Asp)5]2 exhibited significantly lower accumulation in normal bone of mice than did 99mTc-MDP. In osteogenic tumor bearing model rats, 99mTc-EC-[(d-Asp)5]2 accumulated in the osteogenic and normal bone region similar to and lower than 99mTc- MDP, respectively. Although further studies including the chain length of d-Asp are required, these findings indicated that the present chemical design of 99mTc-labeled probe would be applicable to develop 99mTc-labeled probes for selective imaging of osteogenic bone region as well as develop therapeutic agents using therapeutic radionuclides such as 90Y, 177Lu, 186Re, or 188Re and cytotoxic agents to osteogenic bone tumor region.

UR - http://www.scopus.com/inward/record.url?scp=84880378621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880378621&partnerID=8YFLogxK

U2 - 10.1021/bc400197f

DO - 10.1021/bc400197f

M3 - Article

VL - 24

SP - 1248

EP - 1255

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 7

ER -